More specifically, AZD1775 sensitizes cancer cells to therapies that interfere with DNA synthesis and repair processes (i.e., HR), suggesting that certain DNA replication/repair proteins can serve as key determinants of AZD1775 sensitivity, in addition to p53 status [223]. This evidence concerns the gene TP53 and cancer.